New technology now being considered by the FDA for approval can capture coronary inflammation on CCTA images and provide risk assessments. What could this mean for the future of cardiac care? We spoke to one researcher to learn more.
Smaller health systems are increasingly moving into this realm. Tim Kearns, director of marketing and healthcare IT, Konica Minolta Imaging USA, explains the implications.
Nina Kottler, MD, associate CMO for clinical AI at Radiology Partners, explains the movement toward greater regulation of artificial intelligence and the need to test for bias.
Jessica Porembka, MD, of the breast imaging division at University of Texas Southwestern Medical Center, said an ultrasound-first strategy for these lesions in DBT is cost-effective and improves efficiency.
New technology now being considered by the FDA for approval can capture coronary inflammation on CCTA images and provide risk assessments. What could this mean for the future of cardiac care? We spoke to one researcher to learn more.
Smaller health systems are increasingly moving into this realm. Tim Kearns, director of marketing and healthcare IT, Konica Minolta Imaging USA, explains the implications.
Nina Kottler, MD, associate CMO for clinical AI at Radiology Partners, explains the movement toward greater regulation of artificial intelligence and the need to test for bias.
Jessica Porembka, MD, of the breast imaging division at University of Texas Southwestern Medical Center, said an ultrasound-first strategy for these lesions in DBT is cost-effective and improves efficiency.
Melissa Davis, MD, vice chair of medical informatics and associate professor at Yale University’s Department of Radiology and Biomedical Imaging, shares her findings from research on private equity market penetration.
Radiologist Jessica Porembka, MD, FSBI, an associate professor with the breast imaging division at University of Texas Southwestern Medical Center, explains what it means when a mammography report says a patient has architectural distortion.
To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.
Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.
